The world is currently experiencing a huge challenge which has affected all the industries and markets. Few markets have experienced a high growth in their demand while others have faced a downfall. The extent of growth or drop in the market statistics of different industries by COVID 19 plays an important role in how the future of businesses will shape up in the near future. We at Value Market Research provide you with an impact analysis of COVID 19 on this market with its latest update in the purchased version of the report.
Global Cutaneous Leishmaniasis Drugs Market Report By Product Type (Pentavalent Antimonials, Antifungal Drugs, Anti-Leishmanial/Antimicrobial Drugs), By Application (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2021-2028
ID:VMR11214193
April 2021
Report Formats: Electronic (PDF), MS EXCEL
The global demand for Cutaneous Leishmaniasis Drugs Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period 2022 - 2028.
Cutaneous leishmaniasis drugs are medications used to treat a protozoal infection transmitted by sandfly bite. They cover a clinical spectrum of diseases caused due to this infection ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. The various treatment methods include oral drugs like itraconazole and fluconazole, oral antibiotics (rifampicin, metronidazole, cotrimoxazole), intravenous or topical amphotericin B, oral dapsone, photodynamic therapy, promoting healing therapies, laser, or cryotherapy treatments. The suitable treatment mode is determined by the cost, availability of drugs, side effects, and the local experience. However, the results of these treatment methods have not been well established in children, women of childbearing age, patients with comorbidities, and immunocompromised patients.
Market Dynamics
The devastating effect the non-life-threatening cutaneous leishmaniasis has on the local community is the main impetus for this market's growth. The high spread of this disease among travelers and environmental changes like deforestation and agricultural practices will further enhance these drugs' market. The disfiguring skin lesions leaving life-long scars leading to severe social stigma will increase the demand for these drugs, especially among women and children. Increased government initiatives to curtail the spread of the diseases due to the dire consequences on the local community like ostracism, less education, and economic loss will benefit market growth. The continued research to develop an entirely new generation of all-oral drugs to treat cutaneous leishmaniasis will be a market booster. The high costs of ensuring access to medicines and the challenges involved in implementing efficient control programs, especially in low-income countries where leishmaniasis spreads rapidly, are the main hindrances of this market.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cutaneous leishmaniasis drugs. The growth and trends of cutaneous leishmaniasis drugs industry provide a holistic approach to this study.
Market Segmentation
This section of the cutaneous leishmaniasis drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Product Type
This section covers the regional outlook, which accentuates current and future demand for the Cutaneous Leishmaniasis Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Cutaneous Leishmaniasis Drugs Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cutaneous leishmaniasis drugs market include Knight Therapeutics, gland pharma, Sanofi, Novartis, GloxoSmithKline, Pfizer, Cheplapharm Arzneimittel GmbH and Jassen Pharmaceutical. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
Cutaneous leishmaniasis drugs are medications used to treat a protozoal infection transmitted by sandfly bite. They cover a clinical spectrum of diseases caused due to this infection ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. The various treatment methods include oral drugs like itraconazole and fluconazole, oral antibiotics (rifampicin, metronidazole, cotrimoxazole), intravenous or topical amphotericin B, oral dapsone, photodynamic therapy, promoting healing therapies, laser, or cryotherapy treatments. The suitable treatment mode is determined by the cost, availability of drugs, side effects, and the local experience. However, the results of these treatment methods have not been well established in children, women of childbearing age, patients with comorbidities, and immunocompromised patients.
Market Dynamics
The devastating effect the non-life-threatening cutaneous leishmaniasis has on the local community is the main impetus for this market's growth. The high spread of this disease among travelers and environmental changes like deforestation and agricultural practices will further enhance these drugs' market. The disfiguring skin lesions leaving life-long scars leading to severe social stigma will increase the demand for these drugs, especially among women and children. Increased government initiatives to curtail the spread of the diseases due to the dire consequences on the local community like ostracism, less education, and economic loss will benefit market growth. The continued research to develop an entirely new generation of all-oral drugs to treat cutaneous leishmaniasis will be a market booster. The high costs of ensuring access to medicines and the challenges involved in implementing efficient control programs, especially in low-income countries where leishmaniasis spreads rapidly, are the main hindrances of this market.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cutaneous leishmaniasis drugs. The growth and trends of cutaneous leishmaniasis drugs industry provide a holistic approach to this study.
Market Segmentation
This section of the cutaneous leishmaniasis drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Product Type
- Pentavalent Antimonials
- Antifungal Drugs
- Anti-Leishmanial/Antimicrobial Drugs
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
This section covers the regional outlook, which accentuates current and future demand for the Cutaneous Leishmaniasis Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Cutaneous Leishmaniasis Drugs Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cutaneous leishmaniasis drugs market include Knight Therapeutics, gland pharma, Sanofi, Novartis, GloxoSmithKline, Pfizer, Cheplapharm Arzneimittel GmbH and Jassen Pharmaceutical. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . CUTANEOUS LEISHMANIASIS DRUGS – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 By Product Type
3.7.2 By Application
3.7.3 By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
5.1. Impact Analysis of Covid-19 Outbreak
5.1.1. Direct Impact on Production
5.1.2. Supply Chain and Market Disruption
5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET ANALYSIS BY PRODUCT TYPE
6.1 Overview by Product Type
6.2 Historical and Forecast Data
6.3 Analysis by Product Type
6.4 Pentavalent Antimonials Market by Regions
6.5 Antifungal Drugs Market by Regions
6.6 Anti-Leishmanial/Antimicrobial Drugs Market by Regions
7 . GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET ANALYSIS BY APPLICATION
7.1 Overview by Application
7.2 Historical and Forecast Data
7.3 Analysis by Application
7.4 Hospitals Pharmacies Market by Regions
7.5 Retail Pharmacies Market by Regions
7.6 Online Pharmacies Market by Regions
8 . GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET ANALYSIS BY GEOGRAPHY
8.1. Regional Outlook
8.2. Introduction
8.3. North America
8.3.1. Overview, Historic and Forecast Data
8.3.2. North America By Segment
8.3.3. North America By Country
8.3.4. United State
8.3.5. Canada
8.3.6. Mexico
8.4. Europe
8.4.1. Overview, Historic and Forecast Data
8.4.2. Europe by Segment
8.4.3. Europe by Country
8.4.4. United Kingdom
8.4.5. France
8.4.6. Germany
8.4.7. Italy
8.4.8. Russia
8.4.9. Rest Of Europe
8.5. Asia Pacific
8.5.1. Overview, Historic and Forecast Data
8.5.2. Asia Pacific by Segment
8.5.3. Asia Pacific by Country
8.5.4. China
8.5.5. India
8.5.6. Japan
8.5.7. South Korea
8.5.8. Australia
8.5.9. Rest Of Asia Pacific
8.6. Latin America
8.6.1. Overview, Historic and Forecast Data
8.6.2. Latin America by Segment
8.6.3. Latin America by Country
8.6.4. Brazil
8.6.5. Argentina
8.6.6. Peru
8.6.7. Chile
8.6.8. Rest of Latin America
8.7. Middle East & Africa
8.7.1. Overview, Historic and Forecast Data
8.7.2. Middle East & Africa by Segment
8.7.3. Middle East & Africa by Country
8.7.4. Saudi Arabia
8.7.5. UAE
8.7.6. Israel
8.7.7. South Africa
8.7.8. Rest Of Middle East And Africa
9 . COMPETITIVE LANDSCAPE OF THE CUTANEOUS LEISHMANIASIS DRUGS COMPANIES
9.1. Cutaneous Leishmaniasis Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments
10 . COMPANY PROFILES OF CUTANEOUS LEISHMANIASIS DRUGS INDUSTRY
10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Knight Therapeutics
10.3.1. Company Overview
10.3.2. Financials
10.3.3. Products
10.3.4. Recent Developments
10.4. Gland Pharma
10.4.1. Company Overview
10.4.2. Financials
10.4.3. Products
10.4.4. Recent Developments
10.5. Sanofi
10.5.1. Company Overview
10.5.2. Financials
10.5.3. Products
10.5.4. Recent Developments
10.6. Novartis
10.6.1. Company Overview
10.6.2. Financials
10.6.3. Products
10.6.4. Recent Developments
10.7. GloxoSmithKline
10.7.1. Company Overview
10.7.2. Financials
10.7.3. Products
10.7.4. Recent Developments
10.8. Pfizer
10.8.1. Company Overview
10.8.2. Financials
10.8.3. Products
10.8.4. Recent Developments
10.9. Cheplapharm Arzneimittel GmbH
10.9.1. Company Overview
10.9.2. Financials
10.9.3. Products
10.9.4. Recent Developments
10.10. Jassen Pharmaceutical
10.10.1. Company Overview
10.10.2. Financials
10.10.3. Products
10.10.4. Recent Developments
*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- COVID-19 Impact Analysis by Production, Import, Export and Demand
- Pre V/S Post COVID-19
- Estimated Impact Of The Coronavirus (Covid-19) Epidemic
- COVID-19: Micro and Macro Factor Analysis
- Analysis by Product Type (USD MN)
- Pentavalent Antimonials Market by Geography (USD MN)
- Antifungal Drugs Market by Geography (USD MN)
- Anti-Leishmanial/Antimicrobial Drugs Market by Geography (USD MN)
- Analysis Market by Application (USD MN)
- Hospitals Pharmacies Market by Geography (USD MN)
- Retail Pharmacies Market by Geography (USD MN)
- Online Pharmacies Market by Geography (USD MN)
- Global Cutaneous Leishmaniasis Drugs Market by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisiton
LIST OF FIGURES
- Research Scope of Cutaneous Leishmaniasis Drugs Report
- Market Research Process
- Market Research Methodology
- Global Cutaneous Leishmaniasis Drugs Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Product Type
- Market Attractiveness Analysis by Application
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Product Type (USD MN)
- Pentavalent Antimonials Market by Geography (USD MN)
- Antifungal Drugs Market by Geography (USD MN)
- Anti-Leishmanial/Antimicrobial Drugs Market by Geography (USD MN)
- Global Market Analysis by Application (USD MN)
- Hospitals Pharmacies Market by Geography (USD MN)
- Retail Pharmacies Market by Geography (USD MN)
- Online Pharmacies Market by Geography (USD MN)
- Global Market by Revenue
- North America Market by Revenue
- Europe Market by Revenue
- Asia Pacific Market by Revenue
- Latin America Market by Revenue
- Middle East & Africa Market by Revenue
- Recent Development in Industry
- Company Market Share Analysis
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
Related Categories
Pharmaceuticals
Buy Chapters or Sections
Avail customized purchase options to meet your exact research needs:
- Buy sections of this report
- Buy country level reports
- Request for historical data
- Request discounts available for Start-Ups & Universities
Objectives of Study
- Define and measure the global market
- Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
- Analyze and identify major market trends along with the factors driving or inhibiting the market growth
- Study the company profiles of the major market players with their market share
- Analyze competitive developments